FareedKhan
commited on
Commit
•
8ef8bbe
1
Parent(s):
a2e234c
Add new SentenceTransformer model.
Browse files- .gitattributes +1 -0
- 1_Pooling/config.json +10 -0
- README.md +715 -0
- config.json +28 -0
- config_sentence_transformers.json +10 -0
- model.safetensors +3 -0
- modules.json +20 -0
- sentence_bert_config.json +4 -0
- special_tokens_map.json +55 -0
- tokenizer.json +3 -0
- tokenizer_config.json +81 -0
.gitattributes
CHANGED
@@ -33,3 +33,4 @@ saved_model/**/* filter=lfs diff=lfs merge=lfs -text
|
|
33 |
*.zip filter=lfs diff=lfs merge=lfs -text
|
34 |
*.zst filter=lfs diff=lfs merge=lfs -text
|
35 |
*tfevents* filter=lfs diff=lfs merge=lfs -text
|
|
|
|
33 |
*.zip filter=lfs diff=lfs merge=lfs -text
|
34 |
*.zst filter=lfs diff=lfs merge=lfs -text
|
35 |
*tfevents* filter=lfs diff=lfs merge=lfs -text
|
36 |
+
tokenizer.json filter=lfs diff=lfs merge=lfs -text
|
1_Pooling/config.json
ADDED
@@ -0,0 +1,10 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
{
|
2 |
+
"word_embedding_dimension": 1024,
|
3 |
+
"pooling_mode_cls_token": false,
|
4 |
+
"pooling_mode_mean_tokens": true,
|
5 |
+
"pooling_mode_max_tokens": false,
|
6 |
+
"pooling_mode_mean_sqrt_len_tokens": false,
|
7 |
+
"pooling_mode_weightedmean_tokens": false,
|
8 |
+
"pooling_mode_lasttoken": false,
|
9 |
+
"include_prompt": true
|
10 |
+
}
|
README.md
ADDED
@@ -0,0 +1,715 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
---
|
2 |
+
base_model: mixedbread-ai/deepset-mxbai-embed-de-large-v1
|
3 |
+
library_name: sentence-transformers
|
4 |
+
metrics:
|
5 |
+
- cosine_accuracy@1
|
6 |
+
- cosine_accuracy@3
|
7 |
+
- cosine_accuracy@5
|
8 |
+
- cosine_accuracy@10
|
9 |
+
- cosine_precision@1
|
10 |
+
- cosine_precision@3
|
11 |
+
- cosine_precision@5
|
12 |
+
- cosine_precision@10
|
13 |
+
- cosine_recall@1
|
14 |
+
- cosine_recall@3
|
15 |
+
- cosine_recall@5
|
16 |
+
- cosine_recall@10
|
17 |
+
- cosine_ndcg@10
|
18 |
+
- cosine_mrr@10
|
19 |
+
- cosine_map@100
|
20 |
+
pipeline_tag: sentence-similarity
|
21 |
+
tags:
|
22 |
+
- sentence-transformers
|
23 |
+
- sentence-similarity
|
24 |
+
- feature-extraction
|
25 |
+
- generated_from_trainer
|
26 |
+
- dataset_size:1814
|
27 |
+
- loss:MatryoshkaLoss
|
28 |
+
- loss:MultipleNegativesRankingLoss
|
29 |
+
widget:
|
30 |
+
- source_sentence: '
|
31 |
+
|
32 |
+
The document you provided seems to be a list of compounds, some of which are well-known
|
33 |
+
drugs or drugs used in experimental contexts, and others that don''t appear to
|
34 |
+
have recognized applications in medicine or science. The list includes substances
|
35 |
+
like cortisol, a hormone, and filopram, which is related to anesthetics or possibly
|
36 |
+
a misprint or misclassification. The side effects listed are also a mix, with
|
37 |
+
some being plausible reactions to certain medication (like Edema, dysphagia) and
|
38 |
+
others being quite unusual for commonly recognized drug interactions (like retinal
|
39 |
+
vein occlusion, which is not a typical side effect of most medications).
|
40 |
+
|
41 |
+
|
42 |
+
It would be useful to have labels or references indicating which of these compounds
|
43 |
+
are actually drugs and which are other chemical substances. For instance, cortisol,
|
44 |
+
if given its correct context, would typically have side effects associated with
|
45 |
+
cortisol therapy such as fluid retention or electrolyte imbalances.
|
46 |
+
|
47 |
+
|
48 |
+
If you need detailed information on how these substances work or what their possible
|
49 |
+
side effects might be, you''ll likely need to refer to a medical compendium or
|
50 |
+
a pharmacology resource for accurate data. It''s also important to clarify the
|
51 |
+
intended use for this list, whether for educational purposes, research, or another
|
52 |
+
context; the provided list appears to be a jumbled amalgamation, which might not
|
53 |
+
have clear clinical relevance without additional detail.'
|
54 |
+
sentences:
|
55 |
+
- Can you suggest medications targeting the GC gene/protein with a proven synergy
|
56 |
+
with AVE9633?
|
57 |
+
- Could you help identify the gene or protein that facilitates sodium-dependent
|
58 |
+
transportation and elimination of organic anions, with a particular emphasis on
|
59 |
+
those implicated in the cellular efflux of potentially hazardous organic anions?
|
60 |
+
Additionally, I'm interested in understanding if this gene or protein also mediates
|
61 |
+
the transport of drugs known to exhibit synergistic pharmacological interactions
|
62 |
+
with Ractopamine.
|
63 |
+
- Can you list the medications suitable for benign prostatic hyperplasia and tell
|
64 |
+
me if any are linked to dysphagia as a side effect?
|
65 |
+
- source_sentence: '
|
66 |
+
|
67 |
+
|
68 |
+
The provided information describes a gene that plays a role in multiple biological
|
69 |
+
processes and is linked with certain diseases. Here'
|
70 |
+
sentences:
|
71 |
+
- Which genes or proteins interact with the "Regulation of HSF1-mediated heat shock
|
72 |
+
response" pathway and also engage in protein-protein interactions with PRNP?
|
73 |
+
- Which anatomical parts lack the expression of genes or proteins involved in the
|
74 |
+
L-alanine degradation pathway?
|
75 |
+
- What is the name of a disease classified as a variant or subtype of sinoatrial
|
76 |
+
node disease in the latest medical disease taxonomy?
|
77 |
+
- source_sentence: '
|
78 |
+
|
79 |
+
The list you''ve provided contains a variety of medications, including antidepressants,
|
80 |
+
antihistamines, anxiolytics, and more. Here''s a breakdown by category:
|
81 |
+
|
82 |
+
|
83 |
+
### Antidepressants
|
84 |
+
|
85 |
+
- **Amphetamine**
|
86 |
+
|
87 |
+
- **Cevimeline**
|
88 |
+
|
89 |
+
- **Esmolol**
|
90 |
+
|
91 |
+
- **Bortezomib**
|
92 |
+
|
93 |
+
- **'
|
94 |
+
sentences:
|
95 |
+
- What are some related conditions to triple-negative breast cancer that could be
|
96 |
+
causing persistent fatigue?
|
97 |
+
- Which medication is effective against simple Plasmodium falciparum infections
|
98 |
+
and functions by engaging with genes or proteins that interact with the minor
|
99 |
+
groove of DNA rich in adenine and thymine?
|
100 |
+
- Which diseases associated with SRSF2 gene mutations are primarily found in adults
|
101 |
+
and the elderly?
|
102 |
+
- source_sentence: '
|
103 |
+
|
104 |
+
|
105 |
+
The drug mentioned in the query is "Dabigatran". It belongs to the class of drugs
|
106 |
+
known as direct thrombin inhibitors. This class of drugs is used primarily for
|
107 |
+
the prevention and treatment of thromboembolic disorders.
|
108 |
+
|
109 |
+
|
110 |
+
Regarding potential side effects, they include:
|
111 |
+
|
112 |
+
1. Inflammatory abnormality of the skin (Erythema)
|
113 |
+
|
114 |
+
2. Hemolytic anemia (a type of anemia where red blood cells are destroyed prematurely)
|
115 |
+
|
116 |
+
3. Thrombocytopenia (low platelet count)
|
117 |
+
|
118 |
+
4. Pancytopenia (a decrease in the number of all types of blood cells - red, white,
|
119 |
+
and platelet cells)
|
120 |
+
|
121 |
+
5. Fever
|
122 |
+
|
123 |
+
6. Pain
|
124 |
+
|
125 |
+
7. Seizure
|
126 |
+
|
127 |
+
8. Headache
|
128 |
+
|
129 |
+
9. Vomiting
|
130 |
+
|
131 |
+
10. Abdominal pain
|
132 |
+
|
133 |
+
11. Hyperactivity
|
134 |
+
|
135 |
+
12. Erythroderma (a type of skin flare characterized by a redness over the trunk
|
136 |
+
and limbs)
|
137 |
+
|
138 |
+
13. Vertigo (a sensation of spinning or motion)
|
139 |
+
|
140 |
+
14. Granulocytopenia (low neutrophil count)
|
141 |
+
|
142 |
+
15. Pruritus (severe itching)
|
143 |
+
|
144 |
+
16. Confusion
|
145 |
+
|
146 |
+
17. Eosinophilia (a condition characterized by an increased number of eosinophils,
|
147 |
+
a type of white blood cell)
|
148 |
+
|
149 |
+
18. Anaphylactic shock (a serious allergic reaction)
|
150 |
+
|
151 |
+
19. Hyperkinetic movements
|
152 |
+
|
153 |
+
20. Nausea
|
154 |
+
|
155 |
+
21. Acute sinusitis (inflammation of the sinus cavities)
|
156 |
+
|
157 |
+
22. Agitation
|
158 |
+
|
159 |
+
23. Excessive daytime somnolence (excessively sleepy during the day)
|
160 |
+
|
161 |
+
24. Aplastic anemia (a condition where the bone marrow fails to produce enough
|
162 |
+
new blood cells)
|
163 |
+
|
164 |
+
25. Increased blood urea nitrogen (BUN) (a marker of kidney function, indicating
|
165 |
+
the kidneys are not working properly)
|
166 |
+
|
167 |
+
26. Prolonged prothrombin time (an indication of an increased risk of bleeding,
|
168 |
+
due to a reduction in clotting protein)
|
169 |
+
|
170 |
+
27. Recurrent tonsillitis (repeated inflammation of the tonsils)
|
171 |
+
|
172 |
+
|
173 |
+
Dabigatran works by inhibiting thrombin (Factor IIa), an enzyme involved in the
|
174 |
+
clotting process. If any of these side effects are experienced, it is important
|
175 |
+
to seek medical attention or consult with a healthcare provider.'
|
176 |
+
sentences:
|
177 |
+
- What are the clinical manifestations or phenotypic characteristics associated
|
178 |
+
with the subtype of myocardial infarction known as posteroinferior?
|
179 |
+
- Could you supply a list of drugs prescribed for respiratory infections that may
|
180 |
+
also lead to side effects like hemolytic anemia and nausea?
|
181 |
+
- Which diseases are associated with the FAM111A gene that present with both skeletal
|
182 |
+
and endocrine system abnormalities?
|
183 |
+
- source_sentence: '
|
184 |
+
|
185 |
+
The list you provided seems to be a mix of various chemical substances, some of
|
186 |
+
which appear to be medications, others are chemical compounds, and a few could
|
187 |
+
be substances from other fields (e.g., water treatment, food additives). To be
|
188 |
+
more precise, it would be helpful to categorize them properly based on their common
|
189 |
+
usage:
|
190 |
+
|
191 |
+
|
192 |
+
### Medications and Drugs:
|
193 |
+
|
194 |
+
- **Antibiotics**: Cefoxitin, Tobramycin, Amikacin
|
195 |
+
|
196 |
+
- ** pain and inflammation relievers**: Benoxaprofen, Daptomycin, Ceftolozane,
|
197 |
+
Salicylates (Benzydamine, Dexamethasone sodium phosphate)
|
198 |
+
|
199 |
+
- **Intravenous fluids**: Magnesium trisilicate
|
200 |
+
|
201 |
+
- **Antivirals**: Ribavirin, Inotersen
|
202 |
+
|
203 |
+
- **Antibacterial agents**: Epirizole, Floctafenine, Flunixin
|
204 |
+
|
205 |
+
- **Vaccines**: Vaborbactam, Brincidofovir, Adefovir
|
206 |
+
|
207 |
+
- **Neuromodulators**: Cefatrizine, Bumadizone, Alminoprofen
|
208 |
+
|
209 |
+
- **Cancer treatments**: Colistin, Nitrofurantoin, Sisomicin
|
210 |
+
|
211 |
+
|
212 |
+
### Chemical Compounds:
|
213 |
+
|
214 |
+
- **Salts and salts of acidity**: Fosfomycin, Azosemide, Mofebutazone
|
215 |
+
|
216 |
+
- **Amino acids**: Phenylalanine, Nitrosalicylic'
|
217 |
+
sentences:
|
218 |
+
- Is there a regulatory function associated with the epidermal growth factor receptor
|
219 |
+
or its interacting proteins in the control of genes or proteins that participate
|
220 |
+
in the inactivation of fast sodium channels during Phase 1 of cardiac action potential
|
221 |
+
propagation?
|
222 |
+
- Which diseases, either as subtypes or complications, should be considered when
|
223 |
+
a patient shows symptoms suggesting neoplastic syndromes?
|
224 |
+
- Which drugs interact with the SERPINA1 gene/protein as carriers?
|
225 |
+
model-index:
|
226 |
+
- name: SentenceTransformer based on mixedbread-ai/deepset-mxbai-embed-de-large-v1
|
227 |
+
results:
|
228 |
+
- task:
|
229 |
+
type: information-retrieval
|
230 |
+
name: Information Retrieval
|
231 |
+
dataset:
|
232 |
+
name: dim 768
|
233 |
+
type: dim_768
|
234 |
+
metrics:
|
235 |
+
- type: cosine_accuracy@1
|
236 |
+
value: 0.3910891089108911
|
237 |
+
name: Cosine Accuracy@1
|
238 |
+
- type: cosine_accuracy@3
|
239 |
+
value: 0.4752475247524752
|
240 |
+
name: Cosine Accuracy@3
|
241 |
+
- type: cosine_accuracy@5
|
242 |
+
value: 0.49504950495049505
|
243 |
+
name: Cosine Accuracy@5
|
244 |
+
- type: cosine_accuracy@10
|
245 |
+
value: 0.5544554455445545
|
246 |
+
name: Cosine Accuracy@10
|
247 |
+
- type: cosine_precision@1
|
248 |
+
value: 0.3910891089108911
|
249 |
+
name: Cosine Precision@1
|
250 |
+
- type: cosine_precision@3
|
251 |
+
value: 0.15841584158415842
|
252 |
+
name: Cosine Precision@3
|
253 |
+
- type: cosine_precision@5
|
254 |
+
value: 0.09900990099009901
|
255 |
+
name: Cosine Precision@5
|
256 |
+
- type: cosine_precision@10
|
257 |
+
value: 0.05544554455445544
|
258 |
+
name: Cosine Precision@10
|
259 |
+
- type: cosine_recall@1
|
260 |
+
value: 0.3910891089108911
|
261 |
+
name: Cosine Recall@1
|
262 |
+
- type: cosine_recall@3
|
263 |
+
value: 0.4752475247524752
|
264 |
+
name: Cosine Recall@3
|
265 |
+
- type: cosine_recall@5
|
266 |
+
value: 0.49504950495049505
|
267 |
+
name: Cosine Recall@5
|
268 |
+
- type: cosine_recall@10
|
269 |
+
value: 0.5544554455445545
|
270 |
+
name: Cosine Recall@10
|
271 |
+
- type: cosine_ndcg@10
|
272 |
+
value: 0.4669635292605997
|
273 |
+
name: Cosine Ndcg@10
|
274 |
+
- type: cosine_mrr@10
|
275 |
+
value: 0.439788621719315
|
276 |
+
name: Cosine Mrr@10
|
277 |
+
- type: cosine_map@100
|
278 |
+
value: 0.44615433269461197
|
279 |
+
name: Cosine Map@100
|
280 |
+
---
|
281 |
+
|
282 |
+
# SentenceTransformer based on mixedbread-ai/deepset-mxbai-embed-de-large-v1
|
283 |
+
|
284 |
+
This is a [sentence-transformers](https://www.SBERT.net) model finetuned from [mixedbread-ai/deepset-mxbai-embed-de-large-v1](https://huggingface.co/mixedbread-ai/deepset-mxbai-embed-de-large-v1) on the json dataset. It maps sentences & paragraphs to a 1024-dimensional dense vector space and can be used for semantic textual similarity, semantic search, paraphrase mining, text classification, clustering, and more.
|
285 |
+
|
286 |
+
## Model Details
|
287 |
+
|
288 |
+
### Model Description
|
289 |
+
- **Model Type:** Sentence Transformer
|
290 |
+
- **Base model:** [mixedbread-ai/deepset-mxbai-embed-de-large-v1](https://huggingface.co/mixedbread-ai/deepset-mxbai-embed-de-large-v1) <!-- at revision fe450620a047ac704e100d84aebe7cd3fc137021 -->
|
291 |
+
- **Maximum Sequence Length:** 512 tokens
|
292 |
+
- **Output Dimensionality:** 1024 tokens
|
293 |
+
- **Similarity Function:** Cosine Similarity
|
294 |
+
- **Training Dataset:**
|
295 |
+
- json
|
296 |
+
<!-- - **Language:** Unknown -->
|
297 |
+
<!-- - **License:** Unknown -->
|
298 |
+
|
299 |
+
### Model Sources
|
300 |
+
|
301 |
+
- **Documentation:** [Sentence Transformers Documentation](https://sbert.net)
|
302 |
+
- **Repository:** [Sentence Transformers on GitHub](https://github.com/UKPLab/sentence-transformers)
|
303 |
+
- **Hugging Face:** [Sentence Transformers on Hugging Face](https://huggingface.co/models?library=sentence-transformers)
|
304 |
+
|
305 |
+
### Full Model Architecture
|
306 |
+
|
307 |
+
```
|
308 |
+
SentenceTransformer(
|
309 |
+
(0): Transformer({'max_seq_length': 512, 'do_lower_case': False}) with Transformer model: XLMRobertaModel
|
310 |
+
(1): Pooling({'word_embedding_dimension': 1024, 'pooling_mode_cls_token': False, 'pooling_mode_mean_tokens': True, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})
|
311 |
+
(2): Normalize()
|
312 |
+
)
|
313 |
+
```
|
314 |
+
|
315 |
+
## Usage
|
316 |
+
|
317 |
+
### Direct Usage (Sentence Transformers)
|
318 |
+
|
319 |
+
First install the Sentence Transformers library:
|
320 |
+
|
321 |
+
```bash
|
322 |
+
pip install -U sentence-transformers
|
323 |
+
```
|
324 |
+
|
325 |
+
Then you can load this model and run inference.
|
326 |
+
```python
|
327 |
+
from sentence_transformers import SentenceTransformer
|
328 |
+
|
329 |
+
# Download from the 🤗 Hub
|
330 |
+
model = SentenceTransformer("FareedKhan/mixedbread-ai_deepset-mxbai-embed-de-large-v1_FareedKhan_prime_synthetic_data_2k_3_8")
|
331 |
+
# Run inference
|
332 |
+
sentences = [
|
333 |
+
'\nThe list you provided seems to be a mix of various chemical substances, some of which appear to be medications, others are chemical compounds, and a few could be substances from other fields (e.g., water treatment, food additives). To be more precise, it would be helpful to categorize them properly based on their common usage:\n\n### Medications and Drugs:\n- **Antibiotics**: Cefoxitin, Tobramycin, Amikacin\n- ** pain and inflammation relievers**: Benoxaprofen, Daptomycin, Ceftolozane, Salicylates (Benzydamine, Dexamethasone sodium phosphate)\n- **Intravenous fluids**: Magnesium trisilicate\n- **Antivirals**: Ribavirin, Inotersen\n- **Antibacterial agents**: Epirizole, Floctafenine, Flunixin\n- **Vaccines**: Vaborbactam, Brincidofovir, Adefovir\n- **Neuromodulators**: Cefatrizine, Bumadizone, Alminoprofen\n- **Cancer treatments**: Colistin, Nitrofurantoin, Sisomicin\n\n### Chemical Compounds:\n- **Salts and salts of acidity**: Fosfomycin, Azosemide, Mofebutazone\n- **Amino acids**: Phenylalanine, Nitrosalicylic',
|
334 |
+
'Which drugs interact with the SERPINA1 gene/protein as carriers?',
|
335 |
+
'Is there a regulatory function associated with the epidermal growth factor receptor or its interacting proteins in the control of genes or proteins that participate in the inactivation of fast sodium channels during Phase 1 of cardiac action potential propagation?',
|
336 |
+
]
|
337 |
+
embeddings = model.encode(sentences)
|
338 |
+
print(embeddings.shape)
|
339 |
+
# [3, 1024]
|
340 |
+
|
341 |
+
# Get the similarity scores for the embeddings
|
342 |
+
similarities = model.similarity(embeddings, embeddings)
|
343 |
+
print(similarities.shape)
|
344 |
+
# [3, 3]
|
345 |
+
```
|
346 |
+
|
347 |
+
<!--
|
348 |
+
### Direct Usage (Transformers)
|
349 |
+
|
350 |
+
<details><summary>Click to see the direct usage in Transformers</summary>
|
351 |
+
|
352 |
+
</details>
|
353 |
+
-->
|
354 |
+
|
355 |
+
<!--
|
356 |
+
### Downstream Usage (Sentence Transformers)
|
357 |
+
|
358 |
+
You can finetune this model on your own dataset.
|
359 |
+
|
360 |
+
<details><summary>Click to expand</summary>
|
361 |
+
|
362 |
+
</details>
|
363 |
+
-->
|
364 |
+
|
365 |
+
<!--
|
366 |
+
### Out-of-Scope Use
|
367 |
+
|
368 |
+
*List how the model may foreseeably be misused and address what users ought not to do with the model.*
|
369 |
+
-->
|
370 |
+
|
371 |
+
## Evaluation
|
372 |
+
|
373 |
+
### Metrics
|
374 |
+
|
375 |
+
#### Information Retrieval
|
376 |
+
* Dataset: `dim_768`
|
377 |
+
* Evaluated with [<code>InformationRetrievalEvaluator</code>](https://sbert.net/docs/package_reference/sentence_transformer/evaluation.html#sentence_transformers.evaluation.InformationRetrievalEvaluator)
|
378 |
+
|
379 |
+
| Metric | Value |
|
380 |
+
|:--------------------|:-----------|
|
381 |
+
| cosine_accuracy@1 | 0.3911 |
|
382 |
+
| cosine_accuracy@3 | 0.4752 |
|
383 |
+
| cosine_accuracy@5 | 0.495 |
|
384 |
+
| cosine_accuracy@10 | 0.5545 |
|
385 |
+
| cosine_precision@1 | 0.3911 |
|
386 |
+
| cosine_precision@3 | 0.1584 |
|
387 |
+
| cosine_precision@5 | 0.099 |
|
388 |
+
| cosine_precision@10 | 0.0554 |
|
389 |
+
| cosine_recall@1 | 0.3911 |
|
390 |
+
| cosine_recall@3 | 0.4752 |
|
391 |
+
| cosine_recall@5 | 0.495 |
|
392 |
+
| cosine_recall@10 | 0.5545 |
|
393 |
+
| cosine_ndcg@10 | 0.467 |
|
394 |
+
| cosine_mrr@10 | 0.4398 |
|
395 |
+
| **cosine_map@100** | **0.4462** |
|
396 |
+
|
397 |
+
<!--
|
398 |
+
## Bias, Risks and Limitations
|
399 |
+
|
400 |
+
*What are the known or foreseeable issues stemming from this model? You could also flag here known failure cases or weaknesses of the model.*
|
401 |
+
-->
|
402 |
+
|
403 |
+
<!--
|
404 |
+
### Recommendations
|
405 |
+
|
406 |
+
*What are recommendations with respect to the foreseeable issues? For example, filtering explicit content.*
|
407 |
+
-->
|
408 |
+
|
409 |
+
## Training Details
|
410 |
+
|
411 |
+
### Training Dataset
|
412 |
+
|
413 |
+
#### json
|
414 |
+
|
415 |
+
* Dataset: json
|
416 |
+
* Size: 1,814 training samples
|
417 |
+
* Columns: <code>positive</code> and <code>anchor</code>
|
418 |
+
* Approximate statistics based on the first 1000 samples:
|
419 |
+
| | positive | anchor |
|
420 |
+
|:--------|:------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------|
|
421 |
+
| type | string | string |
|
422 |
+
| details | <ul><li>min: 3 tokens</li><li>mean: 267.06 tokens</li><li>max: 512 tokens</li></ul> | <ul><li>min: 15 tokens</li><li>mean: 39.66 tokens</li><li>max: 120 tokens</li></ul> |
|
423 |
+
* Samples:
|
424 |
+
| positive | anchor |
|
425 |
+
|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------|
|
426 |
+
| <code><br><br>Based on the provided information, it appears you are describing a complex biological system involving various molecules, drugs, diseases, and anatomical structures. Here's a breakdown:<br><br>### Key Entities<br>1. **Molecules and Targets**<br> - Mentioned molecules include metabolites, phenols, and drugs, with specific functional groups related to their chemical properties.<br> - Targets include enzymes (like acetyl-CoA carboxylase) and diseases causing various health conditions (e.g., Finnish type amyloidosis, lung cancer).<br><br>2. **Functionality and Interactions**<br> - The molecules and drugs interact with various biological processes, pathways, and bodily systems.<br></code> | <code>Identify common genetic targets that interact with both N-(3,5-dibromo-4-hydroxyphenyl)benzamide and 1-Naphthylamine-5-sulfonic acid.</code> |
|
427 |
+
| <code><br>The provided list appears to be a collection of gene symbols related to cancer. Gene symbols are used in genetics and molecular biology to identify genes. Each symbol is associated with a specific gene that plays a role in cellular functions, including cancer processes. When studying cancer, researchers often analyze these genes to understand their roles in tumor development, potential as targets for therapy, or as indicators for patient prognosis. For example, some genes listed are known oncogenes or tumor suppressor genes:<br><br>- TP53: A tumor suppressor gene that when mutated can lead to uncontrolled cell growth.<br>- P53, POLD1, PTEN: These are well-known tumor suppressors that help regulate cell division and DNA repair.<br>- BRCA</code> | <code>Which anatomical structures lack expression of genes or proteins involved in the homogentisate degradation pathway?</code> |
|
428 |
+
| <code><br><br>The gene in question appears to have a wide range of functions across various biological processes and body systems. It's involved in several key areas that regulate cellular responses, metabolic processes, and organ development. Here is a summary of its potential roles:<br><br>1. **Cell Growth and Regulation**: The gene contributes to growth control in cells, particularly in smooth muscle cells, and seems to influence cell proliferation, which is essential for tissue repair and development.<br><br>2. **Nerve Function**: It plays a role in functions like signal transduction, neurotrophin signaling, and regulation of neural activity, suggesting it’s involved in neural health and development.<br><br>3. **Metabolic Processes**: There is evidence linking</code> | <code>Identify genes or proteins that interact with angiotensin-converting enzyme 2 (ACE2) and are linked to a common phenotype or effect.</code> |
|
429 |
+
* Loss: [<code>MatryoshkaLoss</code>](https://sbert.net/docs/package_reference/sentence_transformer/losses.html#matryoshkaloss) with these parameters:
|
430 |
+
```json
|
431 |
+
{
|
432 |
+
"loss": "MultipleNegativesRankingLoss",
|
433 |
+
"matryoshka_dims": [
|
434 |
+
768
|
435 |
+
],
|
436 |
+
"matryoshka_weights": [
|
437 |
+
1
|
438 |
+
],
|
439 |
+
"n_dims_per_step": -1
|
440 |
+
}
|
441 |
+
```
|
442 |
+
|
443 |
+
### Training Hyperparameters
|
444 |
+
#### Non-Default Hyperparameters
|
445 |
+
|
446 |
+
- `eval_strategy`: epoch
|
447 |
+
- `learning_rate`: 1e-05
|
448 |
+
- `warmup_ratio`: 0.1
|
449 |
+
- `bf16`: True
|
450 |
+
- `tf32`: False
|
451 |
+
- `load_best_model_at_end`: True
|
452 |
+
|
453 |
+
#### All Hyperparameters
|
454 |
+
<details><summary>Click to expand</summary>
|
455 |
+
|
456 |
+
- `overwrite_output_dir`: False
|
457 |
+
- `do_predict`: False
|
458 |
+
- `eval_strategy`: epoch
|
459 |
+
- `prediction_loss_only`: True
|
460 |
+
- `per_device_train_batch_size`: 8
|
461 |
+
- `per_device_eval_batch_size`: 8
|
462 |
+
- `per_gpu_train_batch_size`: None
|
463 |
+
- `per_gpu_eval_batch_size`: None
|
464 |
+
- `gradient_accumulation_steps`: 1
|
465 |
+
- `eval_accumulation_steps`: None
|
466 |
+
- `torch_empty_cache_steps`: None
|
467 |
+
- `learning_rate`: 1e-05
|
468 |
+
- `weight_decay`: 0.0
|
469 |
+
- `adam_beta1`: 0.9
|
470 |
+
- `adam_beta2`: 0.999
|
471 |
+
- `adam_epsilon`: 1e-08
|
472 |
+
- `max_grad_norm`: 1.0
|
473 |
+
- `num_train_epochs`: 3
|
474 |
+
- `max_steps`: -1
|
475 |
+
- `lr_scheduler_type`: linear
|
476 |
+
- `lr_scheduler_kwargs`: {}
|
477 |
+
- `warmup_ratio`: 0.1
|
478 |
+
- `warmup_steps`: 0
|
479 |
+
- `log_level`: passive
|
480 |
+
- `log_level_replica`: warning
|
481 |
+
- `log_on_each_node`: True
|
482 |
+
- `logging_nan_inf_filter`: True
|
483 |
+
- `save_safetensors`: True
|
484 |
+
- `save_on_each_node`: False
|
485 |
+
- `save_only_model`: False
|
486 |
+
- `restore_callback_states_from_checkpoint`: False
|
487 |
+
- `no_cuda`: False
|
488 |
+
- `use_cpu`: False
|
489 |
+
- `use_mps_device`: False
|
490 |
+
- `seed`: 42
|
491 |
+
- `data_seed`: None
|
492 |
+
- `jit_mode_eval`: False
|
493 |
+
- `use_ipex`: False
|
494 |
+
- `bf16`: True
|
495 |
+
- `fp16`: False
|
496 |
+
- `fp16_opt_level`: O1
|
497 |
+
- `half_precision_backend`: auto
|
498 |
+
- `bf16_full_eval`: False
|
499 |
+
- `fp16_full_eval`: False
|
500 |
+
- `tf32`: False
|
501 |
+
- `local_rank`: 0
|
502 |
+
- `ddp_backend`: None
|
503 |
+
- `tpu_num_cores`: None
|
504 |
+
- `tpu_metrics_debug`: False
|
505 |
+
- `debug`: []
|
506 |
+
- `dataloader_drop_last`: False
|
507 |
+
- `dataloader_num_workers`: 0
|
508 |
+
- `dataloader_prefetch_factor`: None
|
509 |
+
- `past_index`: -1
|
510 |
+
- `disable_tqdm`: False
|
511 |
+
- `remove_unused_columns`: True
|
512 |
+
- `label_names`: None
|
513 |
+
- `load_best_model_at_end`: True
|
514 |
+
- `ignore_data_skip`: False
|
515 |
+
- `fsdp`: []
|
516 |
+
- `fsdp_min_num_params`: 0
|
517 |
+
- `fsdp_config`: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}
|
518 |
+
- `fsdp_transformer_layer_cls_to_wrap`: None
|
519 |
+
- `accelerator_config`: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
|
520 |
+
- `deepspeed`: None
|
521 |
+
- `label_smoothing_factor`: 0.0
|
522 |
+
- `optim`: adamw_torch
|
523 |
+
- `optim_args`: None
|
524 |
+
- `adafactor`: False
|
525 |
+
- `group_by_length`: False
|
526 |
+
- `length_column_name`: length
|
527 |
+
- `ddp_find_unused_parameters`: None
|
528 |
+
- `ddp_bucket_cap_mb`: None
|
529 |
+
- `ddp_broadcast_buffers`: False
|
530 |
+
- `dataloader_pin_memory`: True
|
531 |
+
- `dataloader_persistent_workers`: False
|
532 |
+
- `skip_memory_metrics`: True
|
533 |
+
- `use_legacy_prediction_loop`: False
|
534 |
+
- `push_to_hub`: False
|
535 |
+
- `resume_from_checkpoint`: None
|
536 |
+
- `hub_model_id`: None
|
537 |
+
- `hub_strategy`: every_save
|
538 |
+
- `hub_private_repo`: False
|
539 |
+
- `hub_always_push`: False
|
540 |
+
- `gradient_checkpointing`: False
|
541 |
+
- `gradient_checkpointing_kwargs`: None
|
542 |
+
- `include_inputs_for_metrics`: False
|
543 |
+
- `eval_do_concat_batches`: True
|
544 |
+
- `fp16_backend`: auto
|
545 |
+
- `push_to_hub_model_id`: None
|
546 |
+
- `push_to_hub_organization`: None
|
547 |
+
- `mp_parameters`:
|
548 |
+
- `auto_find_batch_size`: False
|
549 |
+
- `full_determinism`: False
|
550 |
+
- `torchdynamo`: None
|
551 |
+
- `ray_scope`: last
|
552 |
+
- `ddp_timeout`: 1800
|
553 |
+
- `torch_compile`: False
|
554 |
+
- `torch_compile_backend`: None
|
555 |
+
- `torch_compile_mode`: None
|
556 |
+
- `dispatch_batches`: None
|
557 |
+
- `split_batches`: None
|
558 |
+
- `include_tokens_per_second`: False
|
559 |
+
- `include_num_input_tokens_seen`: False
|
560 |
+
- `neftune_noise_alpha`: None
|
561 |
+
- `optim_target_modules`: None
|
562 |
+
- `batch_eval_metrics`: False
|
563 |
+
- `eval_on_start`: False
|
564 |
+
- `use_liger_kernel`: False
|
565 |
+
- `eval_use_gather_object`: False
|
566 |
+
- `batch_sampler`: batch_sampler
|
567 |
+
- `multi_dataset_batch_sampler`: proportional
|
568 |
+
|
569 |
+
</details>
|
570 |
+
|
571 |
+
### Training Logs
|
572 |
+
| Epoch | Step | Training Loss | dim_768_cosine_map@100 |
|
573 |
+
|:-------:|:-------:|:-------------:|:----------------------:|
|
574 |
+
| 0 | 0 | - | 0.3930 |
|
575 |
+
| 0.0441 | 10 | 1.18 | - |
|
576 |
+
| 0.0881 | 20 | 1.0507 | - |
|
577 |
+
| 0.1322 | 30 | 0.9049 | - |
|
578 |
+
| 0.1762 | 40 | 0.8999 | - |
|
579 |
+
| 0.2203 | 50 | 0.6519 | - |
|
580 |
+
| 0.2643 | 60 | 0.5479 | - |
|
581 |
+
| 0.3084 | 70 | 0.6493 | - |
|
582 |
+
| 0.3524 | 80 | 0.4706 | - |
|
583 |
+
| 0.3965 | 90 | 0.5459 | - |
|
584 |
+
| 0.4405 | 100 | 0.5692 | - |
|
585 |
+
| 0.4846 | 110 | 0.7834 | - |
|
586 |
+
| 0.5286 | 120 | 0.5341 | - |
|
587 |
+
| 0.5727 | 130 | 0.5343 | - |
|
588 |
+
| 0.6167 | 140 | 0.4865 | - |
|
589 |
+
| 0.6608 | 150 | 0.3942 | - |
|
590 |
+
| 0.7048 | 160 | 0.3578 | - |
|
591 |
+
| 0.7489 | 170 | 0.5158 | - |
|
592 |
+
| 0.7930 | 180 | 0.3426 | - |
|
593 |
+
| 0.8370 | 190 | 0.5789 | - |
|
594 |
+
| 0.8811 | 200 | 0.5271 | - |
|
595 |
+
| 0.9251 | 210 | 0.577 | - |
|
596 |
+
| 0.9692 | 220 | 0.5193 | - |
|
597 |
+
| 1.0 | 227 | - | 0.4354 |
|
598 |
+
| 1.0132 | 230 | 0.4598 | - |
|
599 |
+
| 1.0573 | 240 | 0.2735 | - |
|
600 |
+
| 1.1013 | 250 | 0.2919 | - |
|
601 |
+
| 1.1454 | 260 | 0.3206 | - |
|
602 |
+
| 1.1894 | 270 | 0.2851 | - |
|
603 |
+
| 1.2335 | 280 | 0.3899 | - |
|
604 |
+
| 1.2775 | 290 | 0.3279 | - |
|
605 |
+
| 1.3216 | 300 | 0.2155 | - |
|
606 |
+
| 1.3656 | 310 | 0.3471 | - |
|
607 |
+
| 1.4097 | 320 | 0.327 | - |
|
608 |
+
| 1.4537 | 330 | 0.229 | - |
|
609 |
+
| 1.4978 | 340 | 0.2902 | - |
|
610 |
+
| 1.5419 | 350 | 0.3216 | - |
|
611 |
+
| 1.5859 | 360 | 0.2902 | - |
|
612 |
+
| 1.6300 | 370 | 0.4527 | - |
|
613 |
+
| 1.6740 | 380 | 0.1583 | - |
|
614 |
+
| 1.7181 | 390 | 0.3144 | - |
|
615 |
+
| 1.7621 | 400 | 0.2573 | - |
|
616 |
+
| 1.8062 | 410 | 0.2309 | - |
|
617 |
+
| 1.8502 | 420 | 0.3475 | - |
|
618 |
+
| 1.8943 | 430 | 0.3082 | - |
|
619 |
+
| 1.9383 | 440 | 0.3176 | - |
|
620 |
+
| 1.9824 | 450 | 0.2104 | - |
|
621 |
+
| **2.0** | **454** | **-** | **0.4453** |
|
622 |
+
| 2.0264 | 460 | 0.2615 | - |
|
623 |
+
| 2.0705 | 470 | 0.1599 | - |
|
624 |
+
| 2.1145 | 480 | 0.1015 | - |
|
625 |
+
| 2.1586 | 490 | 0.2154 | - |
|
626 |
+
| 2.2026 | 500 | 0.1161 | - |
|
627 |
+
| 2.2467 | 510 | 0.2208 | - |
|
628 |
+
| 2.2907 | 520 | 0.2035 | - |
|
629 |
+
| 2.3348 | 530 | 0.1622 | - |
|
630 |
+
| 2.3789 | 540 | 0.1758 | - |
|
631 |
+
| 2.4229 | 550 | 0.2782 | - |
|
632 |
+
| 2.4670 | 560 | 0.303 | - |
|
633 |
+
| 2.5110 | 570 | 0.1787 | - |
|
634 |
+
| 2.5551 | 580 | 0.2221 | - |
|
635 |
+
| 2.5991 | 590 | 0.1686 | - |
|
636 |
+
| 2.6432 | 600 | 0.2522 | - |
|
637 |
+
| 2.6872 | 610 | 0.1334 | - |
|
638 |
+
| 2.7313 | 620 | 0.1102 | - |
|
639 |
+
| 2.7753 | 630 | 0.2499 | - |
|
640 |
+
| 2.8194 | 640 | 0.2648 | - |
|
641 |
+
| 2.8634 | 650 | 0.1859 | - |
|
642 |
+
| 2.9075 | 660 | 0.2385 | - |
|
643 |
+
| 2.9515 | 670 | 0.2283 | - |
|
644 |
+
| 2.9956 | 680 | 0.1126 | - |
|
645 |
+
| 3.0 | 681 | - | 0.4462 |
|
646 |
+
|
647 |
+
* The bold row denotes the saved checkpoint.
|
648 |
+
|
649 |
+
### Framework Versions
|
650 |
+
- Python: 3.10.10
|
651 |
+
- Sentence Transformers: 3.1.1
|
652 |
+
- Transformers: 4.45.1
|
653 |
+
- PyTorch: 2.2.1+cu121
|
654 |
+
- Accelerate: 0.34.2
|
655 |
+
- Datasets: 3.0.1
|
656 |
+
- Tokenizers: 0.20.0
|
657 |
+
|
658 |
+
## Citation
|
659 |
+
|
660 |
+
### BibTeX
|
661 |
+
|
662 |
+
#### Sentence Transformers
|
663 |
+
```bibtex
|
664 |
+
@inproceedings{reimers-2019-sentence-bert,
|
665 |
+
title = "Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks",
|
666 |
+
author = "Reimers, Nils and Gurevych, Iryna",
|
667 |
+
booktitle = "Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing",
|
668 |
+
month = "11",
|
669 |
+
year = "2019",
|
670 |
+
publisher = "Association for Computational Linguistics",
|
671 |
+
url = "https://arxiv.org/abs/1908.10084",
|
672 |
+
}
|
673 |
+
```
|
674 |
+
|
675 |
+
#### MatryoshkaLoss
|
676 |
+
```bibtex
|
677 |
+
@misc{kusupati2024matryoshka,
|
678 |
+
title={Matryoshka Representation Learning},
|
679 |
+
author={Aditya Kusupati and Gantavya Bhatt and Aniket Rege and Matthew Wallingford and Aditya Sinha and Vivek Ramanujan and William Howard-Snyder and Kaifeng Chen and Sham Kakade and Prateek Jain and Ali Farhadi},
|
680 |
+
year={2024},
|
681 |
+
eprint={2205.13147},
|
682 |
+
archivePrefix={arXiv},
|
683 |
+
primaryClass={cs.LG}
|
684 |
+
}
|
685 |
+
```
|
686 |
+
|
687 |
+
#### MultipleNegativesRankingLoss
|
688 |
+
```bibtex
|
689 |
+
@misc{henderson2017efficient,
|
690 |
+
title={Efficient Natural Language Response Suggestion for Smart Reply},
|
691 |
+
author={Matthew Henderson and Rami Al-Rfou and Brian Strope and Yun-hsuan Sung and Laszlo Lukacs and Ruiqi Guo and Sanjiv Kumar and Balint Miklos and Ray Kurzweil},
|
692 |
+
year={2017},
|
693 |
+
eprint={1705.00652},
|
694 |
+
archivePrefix={arXiv},
|
695 |
+
primaryClass={cs.CL}
|
696 |
+
}
|
697 |
+
```
|
698 |
+
|
699 |
+
<!--
|
700 |
+
## Glossary
|
701 |
+
|
702 |
+
*Clearly define terms in order to be accessible across audiences.*
|
703 |
+
-->
|
704 |
+
|
705 |
+
<!--
|
706 |
+
## Model Card Authors
|
707 |
+
|
708 |
+
*Lists the people who create the model card, providing recognition and accountability for the detailed work that goes into its construction.*
|
709 |
+
-->
|
710 |
+
|
711 |
+
<!--
|
712 |
+
## Model Card Contact
|
713 |
+
|
714 |
+
*Provides a way for people who have updates to the Model Card, suggestions, or questions, to contact the Model Card authors.*
|
715 |
+
-->
|
config.json
ADDED
@@ -0,0 +1,28 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
{
|
2 |
+
"_name_or_path": "mixedbread-ai_deepset-mxbai-embed-de-large-v1_FareedKhan_prime_synthetic_data_2k_3_8/finetuned_model",
|
3 |
+
"architectures": [
|
4 |
+
"XLMRobertaModel"
|
5 |
+
],
|
6 |
+
"attention_probs_dropout_prob": 0.1,
|
7 |
+
"bos_token_id": 0,
|
8 |
+
"classifier_dropout": null,
|
9 |
+
"eos_token_id": 2,
|
10 |
+
"hidden_act": "gelu",
|
11 |
+
"hidden_dropout_prob": 0.1,
|
12 |
+
"hidden_size": 1024,
|
13 |
+
"initializer_range": 0.02,
|
14 |
+
"intermediate_size": 4096,
|
15 |
+
"layer_norm_eps": 1e-05,
|
16 |
+
"max_position_embeddings": 514,
|
17 |
+
"model_type": "xlm-roberta",
|
18 |
+
"num_attention_heads": 16,
|
19 |
+
"num_hidden_layers": 24,
|
20 |
+
"output_past": true,
|
21 |
+
"pad_token_id": 1,
|
22 |
+
"position_embedding_type": "absolute",
|
23 |
+
"torch_dtype": "float32",
|
24 |
+
"transformers_version": "4.45.1",
|
25 |
+
"type_vocab_size": 1,
|
26 |
+
"use_cache": false,
|
27 |
+
"vocab_size": 178885
|
28 |
+
}
|
config_sentence_transformers.json
ADDED
@@ -0,0 +1,10 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
{
|
2 |
+
"__version__": {
|
3 |
+
"sentence_transformers": "3.1.1",
|
4 |
+
"transformers": "4.45.1",
|
5 |
+
"pytorch": "2.2.1+cu121"
|
6 |
+
},
|
7 |
+
"prompts": {},
|
8 |
+
"default_prompt_name": null,
|
9 |
+
"similarity_fn_name": null
|
10 |
+
}
|
model.safetensors
ADDED
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
1 |
+
version https://git-lfs.github.com/spec/v1
|
2 |
+
oid sha256:857d73dcb4ddbb0fca11bbe9c0518d3feba1eb6a577392eb977ab31e40e938a9
|
3 |
+
size 1948311760
|
modules.json
ADDED
@@ -0,0 +1,20 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
[
|
2 |
+
{
|
3 |
+
"idx": 0,
|
4 |
+
"name": "0",
|
5 |
+
"path": "",
|
6 |
+
"type": "sentence_transformers.models.Transformer"
|
7 |
+
},
|
8 |
+
{
|
9 |
+
"idx": 1,
|
10 |
+
"name": "1",
|
11 |
+
"path": "1_Pooling",
|
12 |
+
"type": "sentence_transformers.models.Pooling"
|
13 |
+
},
|
14 |
+
{
|
15 |
+
"idx": 2,
|
16 |
+
"name": "2",
|
17 |
+
"path": "2_Normalize",
|
18 |
+
"type": "sentence_transformers.models.Normalize"
|
19 |
+
}
|
20 |
+
]
|
sentence_bert_config.json
ADDED
@@ -0,0 +1,4 @@
|
|
|
|
|
|
|
|
|
|
|
1 |
+
{
|
2 |
+
"max_seq_length": 512,
|
3 |
+
"do_lower_case": false
|
4 |
+
}
|
special_tokens_map.json
ADDED
@@ -0,0 +1,55 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
{
|
2 |
+
"additional_special_tokens": [
|
3 |
+
"[MXBAI_Q]",
|
4 |
+
"[MXBAI_P]"
|
5 |
+
],
|
6 |
+
"bos_token": {
|
7 |
+
"content": "<s>",
|
8 |
+
"lstrip": false,
|
9 |
+
"normalized": false,
|
10 |
+
"rstrip": false,
|
11 |
+
"single_word": false
|
12 |
+
},
|
13 |
+
"cls_token": {
|
14 |
+
"content": "<s>",
|
15 |
+
"lstrip": false,
|
16 |
+
"normalized": false,
|
17 |
+
"rstrip": false,
|
18 |
+
"single_word": false
|
19 |
+
},
|
20 |
+
"eos_token": {
|
21 |
+
"content": "</s>",
|
22 |
+
"lstrip": false,
|
23 |
+
"normalized": false,
|
24 |
+
"rstrip": false,
|
25 |
+
"single_word": false
|
26 |
+
},
|
27 |
+
"mask_token": {
|
28 |
+
"content": "<mask>",
|
29 |
+
"lstrip": true,
|
30 |
+
"normalized": false,
|
31 |
+
"rstrip": false,
|
32 |
+
"single_word": false
|
33 |
+
},
|
34 |
+
"pad_token": {
|
35 |
+
"content": "<pad>",
|
36 |
+
"lstrip": false,
|
37 |
+
"normalized": false,
|
38 |
+
"rstrip": false,
|
39 |
+
"single_word": false
|
40 |
+
},
|
41 |
+
"sep_token": {
|
42 |
+
"content": "</s>",
|
43 |
+
"lstrip": false,
|
44 |
+
"normalized": false,
|
45 |
+
"rstrip": false,
|
46 |
+
"single_word": false
|
47 |
+
},
|
48 |
+
"unk_token": {
|
49 |
+
"content": "<unk>",
|
50 |
+
"lstrip": false,
|
51 |
+
"normalized": false,
|
52 |
+
"rstrip": false,
|
53 |
+
"single_word": false
|
54 |
+
}
|
55 |
+
}
|
tokenizer.json
ADDED
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
1 |
+
version https://git-lfs.github.com/spec/v1
|
2 |
+
oid sha256:b319c37e4f1e5f8f1c8dba7e1bc7b1a424184365d7f982ada0f18ab60c514c07
|
3 |
+
size 12283980
|
tokenizer_config.json
ADDED
@@ -0,0 +1,81 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
{
|
2 |
+
"added_tokens_decoder": {
|
3 |
+
"0": {
|
4 |
+
"content": "<s>",
|
5 |
+
"lstrip": false,
|
6 |
+
"normalized": false,
|
7 |
+
"rstrip": false,
|
8 |
+
"single_word": false,
|
9 |
+
"special": true
|
10 |
+
},
|
11 |
+
"1": {
|
12 |
+
"content": "<pad>",
|
13 |
+
"lstrip": false,
|
14 |
+
"normalized": false,
|
15 |
+
"rstrip": false,
|
16 |
+
"single_word": false,
|
17 |
+
"special": true
|
18 |
+
},
|
19 |
+
"2": {
|
20 |
+
"content": "</s>",
|
21 |
+
"lstrip": false,
|
22 |
+
"normalized": false,
|
23 |
+
"rstrip": false,
|
24 |
+
"single_word": false,
|
25 |
+
"special": true
|
26 |
+
},
|
27 |
+
"3": {
|
28 |
+
"content": "<unk>",
|
29 |
+
"lstrip": false,
|
30 |
+
"normalized": false,
|
31 |
+
"rstrip": false,
|
32 |
+
"single_word": false,
|
33 |
+
"special": true
|
34 |
+
},
|
35 |
+
"178882": {
|
36 |
+
"content": "<mask>",
|
37 |
+
"lstrip": true,
|
38 |
+
"normalized": false,
|
39 |
+
"rstrip": false,
|
40 |
+
"single_word": false,
|
41 |
+
"special": true
|
42 |
+
},
|
43 |
+
"178883": {
|
44 |
+
"content": "[MXBAI_Q]",
|
45 |
+
"lstrip": false,
|
46 |
+
"normalized": false,
|
47 |
+
"rstrip": false,
|
48 |
+
"single_word": false,
|
49 |
+
"special": true
|
50 |
+
},
|
51 |
+
"178884": {
|
52 |
+
"content": "[MXBAI_P]",
|
53 |
+
"lstrip": false,
|
54 |
+
"normalized": false,
|
55 |
+
"rstrip": false,
|
56 |
+
"single_word": false,
|
57 |
+
"special": true
|
58 |
+
}
|
59 |
+
},
|
60 |
+
"additional_special_tokens": [
|
61 |
+
"[MXBAI_Q]",
|
62 |
+
"[MXBAI_P]"
|
63 |
+
],
|
64 |
+
"bos_token": "<s>",
|
65 |
+
"clean_up_tokenization_spaces": true,
|
66 |
+
"cls_token": "<s>",
|
67 |
+
"eos_token": "</s>",
|
68 |
+
"mask_token": "<mask>",
|
69 |
+
"max_length": 512,
|
70 |
+
"model_max_length": 512,
|
71 |
+
"pad_to_multiple_of": null,
|
72 |
+
"pad_token": "<pad>",
|
73 |
+
"pad_token_type_id": 0,
|
74 |
+
"padding_side": "right",
|
75 |
+
"sep_token": "</s>",
|
76 |
+
"stride": 0,
|
77 |
+
"tokenizer_class": "XLMRobertaTokenizer",
|
78 |
+
"truncation_side": "right",
|
79 |
+
"truncation_strategy": "longest_first",
|
80 |
+
"unk_token": "<unk>"
|
81 |
+
}
|